The Arab Drug Company (EGX:ADCI)

Egypt · Delayed Price · Currency is EGP

254.67

-1.52 (-0.59%)

At close: Oct 22, 2026

Market Cap	3.06B +11.7%
Revenue (ttm)	1.37B +22.5%
Net Income	232.38M +16.2%
EPS	19.37 +13.4%
Shares Out	12.00M
PE Ratio	13.15
Forward PE	n/a
Dividend	5.00 (1.96%)
Ex-Dividend Date	Oct 28, 2025

Volume	3,356
Open	256.19
Previous Close	256.19
Day's Range	253.03 - 258.80
52-Week Range	140.00 - 389.99
Beta	0.54
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About The Arab Drug Company

The Arab Drug Company engages in the manufacture and sale of pharmaceutical products. The company offers anti parkinsonism, dermatological, cardiovascular, anti-hypertensive, anti-platelets, analgesic, anti-pyretic, anti-inflammatory, antimigraine, topical anti-fungal, respiratory tract, gynecological, anemia and optic atrophy, oral corticosteroid, anesthetics, topical antiviral, antibacterial and anti-infective, anti-acne, nasal decongestants, anti-diarrheal, antihistamines, mucolytics, antiemetic, allergic rhinitis, anti-vertigo, gingivitis, ... [Read more]

Industry Pharmaceutical Preparations

Founded 1963

Employees 1,148

Stock Exchange Egyptian Stock Exchange

Ticker Symbol ADCI

Full Company Profile

Financial Performance

In fiscal year 2026, The Arab Drug Company's revenue was 1.37 billion, an increase of 22.54% compared to the previous year's 1.12 billion. Earnings were 232.38 million, an increase of 13.43%.

Financial Statements